Product Code: ETC9967100 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 | |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United States (US) Gout Therapeutics Market Overview |
3.1 United States (US) Country Macro Economic Indicators |
3.2 United States (US) Gout Therapeutics Market Revenues & Volume, 2021 & 2031F |
3.3 United States (US) Gout Therapeutics Market - Industry Life Cycle |
3.4 United States (US) Gout Therapeutics Market - Porter's Five Forces |
3.5 United States (US) Gout Therapeutics Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.6 United States (US) Gout Therapeutics Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 United States (US) Gout Therapeutics Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of gout in the United States |
4.2.2 Rising awareness about gout and its treatment options |
4.2.3 Technological advancements in gout therapeutics development |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for approval of gout therapeutics |
4.3.2 Limited accessibility to advanced gout treatments in certain regions |
5 United States (US) Gout Therapeutics Market Trends |
6 United States (US) Gout Therapeutics Market, By Types |
6.1 United States (US) Gout Therapeutics Market, By Drug Type |
6.1.1 Overview and Analysis |
6.1.2 United States (US) Gout Therapeutics Market Revenues & Volume, By Drug Type, 2021- 2031F |
6.1.3 United States (US) Gout Therapeutics Market Revenues & Volume, By NSAIDS, 2021- 2031F |
6.1.4 United States (US) Gout Therapeutics Market Revenues & Volume, By Colchicine, 2021- 2031F |
6.1.5 United States (US) Gout Therapeutics Market Revenues & Volume, By Corticosteroids, 2021- 2031F |
6.1.6 United States (US) Gout Therapeutics Market Revenues & Volume, By Urate-lowering Drugs, 2021- 2031F |
6.1.7 United States (US) Gout Therapeutics Market Revenues & Volume, By Biologics, 2021- 2031F |
6.2 United States (US) Gout Therapeutics Market, By Distribution Channel |
6.2.1 Overview and Analysis |
6.2.2 United States (US) Gout Therapeutics Market Revenues & Volume, By Hospital Pharmacies, 2021- 2031F |
6.2.3 United States (US) Gout Therapeutics Market Revenues & Volume, By Retail Pharmacies, 2021- 2031F |
6.2.4 United States (US) Gout Therapeutics Market Revenues & Volume, By Online Pharmacies, 2021- 2031F |
7 United States (US) Gout Therapeutics Market Import-Export Trade Statistics |
7.1 United States (US) Gout Therapeutics Market Export to Major Countries |
7.2 United States (US) Gout Therapeutics Market Imports from Major Countries |
8 United States (US) Gout Therapeutics Market Key Performance Indicators |
8.1 Patient adherence rate to gout therapeutics |
8.2 Number of new gout therapeutics introduced to the market |
8.3 Average time to market for gout therapeutics innovation |
8.4 Rate of adoption of novel gout treatment approaches |
8.5 Number of partnerships and collaborations in the gout therapeutics sector |
9 United States (US) Gout Therapeutics Market - Opportunity Assessment |
9.1 United States (US) Gout Therapeutics Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
9.2 United States (US) Gout Therapeutics Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 United States (US) Gout Therapeutics Market - Competitive Landscape |
10.1 United States (US) Gout Therapeutics Market Revenue Share, By Companies, 2024 |
10.2 United States (US) Gout Therapeutics Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |